{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T21:40:01Z","timestamp":1794778801319,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Verily Life Sciences LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sensor-based remote monitoring could help better track Parkinson\u2019s disease (PD) progression, and measure patients\u2019 response to putative disease-modifying therapeutic interventions. To be useful, the remotely-collected measurements should be valid, reliable, and sensitive to change, and people with PD must engage with the technology. We developed a smartwatch-based active assessment that enables unsupervised measurement of motor signs of PD. Participants with early-stage PD (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009388, 64% men, average age 63) wore a smartwatch for a median of 390 days. Participants performed unsupervised motor tasks both in-clinic (once) and remotely (twice weekly for one year). Dropout rate was 5.4%. Median wear-time was 21.1\u2009h\/day, and 59% of per-protocol remote assessments were completed. Analytical validation was established for in-clinic measurements, which showed moderate-to-strong correlations with consensus MDS-UPDRS Part III ratings for rest tremor (\u2374\u2009=\u20090.70), bradykinesia (\u2374\u2009=\u2009\u22120.62), and gait (\u2374\u2009=\u2009\u22120.46). Test-retest reliability of remote measurements, aggregated monthly, was good-to-excellent (ICC\u2009=\u20090.75\u20130.96). Remote measurements were sensitive to the known effects of dopaminergic medication (on vs off Cohen\u2019s d\u2009=\u20090.19\u20130.54). Of note, in-clinic assessments often did not reflect the patients\u2019 typical status at home. This demonstrates the feasibility of smartwatch-based unsupervised active tests, and establishes the analytical validity of associated digital measurements. Weekly measurements provide a real-life distribution of disease severity, as it fluctuates longitudinally. Sensitivity to medication-induced change and improved reliability imply that these methods could help reduce sample sizes needed to demonstrate a response to therapeutic interventions or disease progression.\n                  <\/jats:p>","DOI":"10.1038\/s41746-022-00607-8","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T06:04:39Z","timestamp":1653285879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Virtual exam for Parkinson\u2019s disease enables frequent and reliable remote measurements of motor function"],"prefix":"10.1038","volume":"5","author":[{"given":"Maximilien","family":"Burq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1082-7055","authenticated-orcid":false,"given":"Erin","family":"Rainaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"King Chung","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1175-3027","authenticated-orcid":false,"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan R.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc J. W.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick C.","family":"Helmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3796-3604","authenticated-orcid":false,"given":"Lance","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William J.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"607_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R., Ray Dorsey, E., Sherer, T., Okun, M. S. & Bloem, B. R. The emerging evidence of the Parkinson pandemic. J. Parkinson\u2019s Dis. 8, S3\u2013S8 (2018).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"607_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang, A. E. & Espay, A. J. Disease modification in Parkinson\u2019s disease: Current approaches, challenges, and future considerations. Mov. Disord. 33, 660\u2013677 (2018).","journal-title":"Mov. Disord."},{"key":"607_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3233\/JPD-202128","volume":"10","author":"K McFarthing","year":"2020","unstructured":"McFarthing, K. et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2020. J. Parkinsons. Dis. 10, 757\u2013774 (2020).","journal-title":"J. Parkinsons. Dis."},{"key":"607_CR4","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/mds.27790","volume":"34","author":"LJW Evers","year":"2019","unstructured":"Evers, L. J. W., Krijthe, J. H., Meinders, M. J., Bloem, B. R. & Heskes, T. M. Measuring Parkinson\u2019s disease over time: The real-world within-subject reliability of the MDS-UPDRS. Mov. Disord. 34, 1480\u20131487 (2019).","journal-title":"Mov. Disord."},{"key":"607_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41746-020-00334-y","volume":"3","author":"MD Czech","year":"2020","unstructured":"Czech, M. D. et al. Age and environment-related differences in gait in healthy adults using wearables. NPJ Digit Med 3, 127 (2020).","journal-title":"NPJ Digit Med"},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamainternmed.2014.6300","volume":"175","author":"MD Galsky","year":"2015","unstructured":"Galsky, M. D. et al. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern. Med. 175, 293 (2015).","journal-title":"JAMA Intern. Med."},{"key":"607_CR7","doi-asserted-by":"publisher","first-page":"e200172","DOI":"10.1001\/jamanetworkopen.2020.0172","volume":"3","author":"Y Feyman","year":"2020","unstructured":"Feyman, Y., Provenzano, F. & David, F. S. Disparities in clinical trial access across US Urban Areas. JAMA Netw. Open 3, e200172 (2020).","journal-title":"JAMA Netw. Open"},{"key":"607_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S2213-2600(21)00046-1","volume":"9","author":"JE Clougherty","year":"2021","unstructured":"Clougherty, J. E. et al. Geography, generalisability, and susceptibility in clinical trials. Lancet Respir. Med 9, 330\u2013332 (2021).","journal-title":"Lancet Respir. Med"},{"key":"607_CR9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/cts.12834","volume":"13","author":"ES Izmailova","year":"2020","unstructured":"Izmailova, E. S., Ellis, R. & Benko, C. Remote monitoring in clinical trials during the COVID-19 pandemic. Clin. Transl. Sci. 13, 838\u2013841 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"607_CR10","doi-asserted-by":"publisher","first-page":"567413","DOI":"10.3389\/fneur.2020.567413","volume":"11","author":"F Motolese","year":"2020","unstructured":"Motolese, F. et al. Parkinson\u2019s disease remote patient monitoring during the COVID-19 lockdown. Front. Neurol. 11, 567413 (2020).","journal-title":"Front. Neurol."},{"key":"607_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000509725","volume":"4","author":"C Manta","year":"2020","unstructured":"Manta, C., Patrick-Lake, B. & Goldsack, J. C. Digital measures that matter to patients: A framework to guide the selection and development of digital measures of health. Digit Biomark. 4, 69\u201377 (2020).","journal-title":"Digit Biomark."},{"key":"607_CR12","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.3233\/JPD-202428","volume":"11","author":"D Stephenson","year":"2021","unstructured":"Stephenson, D., Badawy, R., Mathur, S., Tome, M. & Rochester, L. Digital progression biomarkers as novel endpoints in clinical trials: A multistakeholder perspective. J. Parkinsons. Dis. 11, S103\u2013S109 (2021).","journal-title":"J. Parkinsons. Dis."},{"key":"607_CR13","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3389\/fneur.2018.01036","volume":"9","author":"JE Thorp","year":"2018","unstructured":"Thorp, J. E., Adamczyk, P. G., Ploeg, H.-L. & Pickett, K. A. Monitoring motor symptoms during activities of daily living in individuals with Parkinson\u2019s disease. Front. Neurol. 9, 1036 (2018).","journal-title":"Front. Neurol."},{"key":"607_CR14","doi-asserted-by":"crossref","unstructured":"Corr\u00e0, M. F. et al. Comparison of laboratory and daily-life gait speed assessment during ON and OFF states in Parkinson\u2019s disease. Sensors 21, (2021).","DOI":"10.3390\/s21123974"},{"key":"607_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41746-019-0217-7","volume":"3","author":"N Mahadevan","year":"2020","unstructured":"Mahadevan, N. et al. Development of digital biomarkers for resting tremor and bradykinesia using a wrist-worn wearable device. NPJ. Digit. Med. 3, 5 (2020).","journal-title":"NPJ. Digit. Med."},{"key":"607_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/ana.25548","volume":"86","author":"S Del Din","year":"2019","unstructured":"Del Din, S. et al. Gait analysis with wearables predicts conversion to parkinson disease. Ann. Neurol. 86, 357\u2013367 (2019).","journal-title":"Ann. Neurol."},{"key":"607_CR17","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/jamaneurol.2018.0809","volume":"75","author":"A Zhan","year":"2018","unstructured":"Zhan, A. et al. Using smartphones and machine learning to quantify Parkinson disease severity: The mobile Parkinson disease score. JAMA Neurol. 75, 876\u2013880 (2018).","journal-title":"JAMA Neurol."},{"key":"607_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41746-018-0071-z","volume":"1","author":"L Lonini","year":"2018","unstructured":"Lonini, L. et al. Wearable sensors for Parkinson\u2019s disease: Which data are worth collecting for training symptom detection models. NPJ Digit. Med. 1, 64 (2018).","journal-title":"NPJ Digit. Med."},{"key":"607_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.parkreldis.2015.02.026","volume":"21","author":"S Arora","year":"2015","unstructured":"Arora, S. et al. Detecting and monitoring the symptoms of Parkinson\u2019s disease using smartphones: A pilot study. Parkinsonism Relat. Disord. 21, 650\u2013653 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"607_CR20","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/mds.26720","volume":"31","author":"A Mirelman","year":"2016","unstructured":"Mirelman, A. et al. Arm swing as a potential new prodromal marker of Parkinson\u2019s disease. Mov. Disord. 31, 1527\u20131534 (2016).","journal-title":"Mov. Disord."},{"key":"607_CR21","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3390\/s21062047","volume":"21","author":"JR Williamson","year":"2021","unstructured":"Williamson, J. R., Telfer, B., Mullany, R. & Friedl, K. E. Detecting Parkinson\u2019s disease from wrist-worn accelerometry in the U.K. Biobank. Sensors 21, 2047 (2021).","journal-title":"Sensors"},{"key":"607_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JPD-160898","volume":"6","author":"M Braybrook","year":"2016","unstructured":"Braybrook, M. et al. An ambulatory tremor score for Parkinson\u2019s disease. J. Parkinsons. Dis. 6, 723\u2013731 (2016).","journal-title":"J. Parkinsons. Dis."},{"key":"607_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/mds.27376","volume":"33","author":"F Lipsmeier","year":"2018","unstructured":"Lipsmeier, F. et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson\u2019s disease clinical trial. Mov. Disord. 33, 1287\u20131297 (2018).","journal-title":"Mov. Disord."},{"key":"607_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.11","volume":"3","author":"BM Bot","year":"2016","unstructured":"Bot, B. M. et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Sci. Data 3, 160011 (2016).","journal-title":"Sci. Data"},{"key":"607_CR25","unstructured":"WATCH-PD: Wearable Assessments in the Clinic and Home in Parkinson\u2019s Disease: Baseline Analyses\u2014MDS Abstracts. https:\/\/www.mdsabstracts.org\/abstract\/watch-pd-wearable-assessments-in-the-clinic-and-home-in-parkinsons-disease-baseline-analyses\/ (2021)."},{"key":"607_CR26","doi-asserted-by":"publisher","unstructured":"Powers, R. et al. Smartwatch inertial sensors continuously monitor real-world motor fluctuations in Parkinson\u2019s disease. Sci. Transl. Med. (2021) https:\/\/doi.org\/10.1126\/scitranslmed.abd7865.","DOI":"10.1126\/scitranslmed.abd7865"},{"key":"607_CR27","doi-asserted-by":"crossref","unstructured":"Bloem, B. R. et al. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson\u2019s disease. BMC Neurol. 19, 160 (2019).","DOI":"10.1186\/s12883-019-1394-3"},{"key":"607_CR28","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1001\/jama.2021.4609","volume":"325","author":"MM McDermott","year":"2021","unstructured":"McDermott, M. M. & Newman, A. B. Remote research and clinical trial integrity during and after the Coronavirus pandemic. JAMA 325, 1935\u20131936 (2021).","journal-title":"JAMA"},{"key":"607_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.22237\/jmasm\/1257035100","volume":"8","author":"SS Sawilowsky","year":"2009","unstructured":"Sawilowsky, S. S. New effect size rules of thumb. J. Mod. Appl. Stat. Methods 8, 597\u2013599 (2009).","journal-title":"J. Mod. Appl. Stat. Methods"},{"key":"607_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jnnp.2009.173740","volume":"81","author":"C Zampieri","year":"2010","unstructured":"Zampieri, C. et al. The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 81, 171\u2013176 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"607_CR31","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/mds.26671","volume":"31","author":"D Haubenberger","year":"2016","unstructured":"Haubenberger, D. et al. Transducer-based evaluation of tremor. Mov. Disord. 31, 1327\u20131336 (2016).","journal-title":"Mov. Disord."},{"key":"607_CR32","doi-asserted-by":"publisher","first-page":"e1095","DOI":"10.1212\/WNL.0000000000005215","volume":"90","author":"MF Dirkx","year":"2018","unstructured":"Dirkx, M. F., Zach, H., Bloem, B. R., Hallett, M. & Helmich, R. C. The nature of postural tremor in Parkinson disease. Neurology 90, e1095\u2013e1103 (2018).","journal-title":"Neurology"},{"key":"607_CR33","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1093\/brain\/awl190","volume":"129","author":"RJ Elble","year":"2006","unstructured":"Elble, R. J. et al. Tremor amplitude is logarithmically related to 4- and 5-point tremor rating scales. Brain 129, 2660\u20132666 (2006).","journal-title":"Brain"},{"key":"607_CR34","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"607_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41746-020-0260-4","volume":"3","author":"JC Goldsack","year":"2020","unstructured":"Goldsack, J. C. et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). NPJ Digit Med 3, 55 (2020).","journal-title":"NPJ Digit Med"},{"key":"607_CR36","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. (Food and Drug Administration (US), 2016)."},{"key":"607_CR37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3233\/JPD-150650","volume":"5","author":"H Zach","year":"2015","unstructured":"Zach, H., Dirkx, M., Bloem, B. R. & Helmich, R. C. The clinical evaluation of Parkinson\u2019s tremor. J. Parkinson\u2019s Dis. 5, 471\u2013474 (2015).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"607_CR38","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/1531-8257(199907)14:4<585::AID-MDS1006>3.0.CO;2-3","volume":"14","author":"GT Stebbins","year":"1999","unstructured":"Stebbins, G. T., Goetz, C. G., Lang, A. E. & Cubo, E. Factor analysis of the motor section of the unified Parkinson\u2019s disease rating scale during the off-state. Mov. Disord. 14, 585\u2013589 (1999).","journal-title":"Mov. Disord."},{"key":"607_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41746-020-0305-8","volume":"3","author":"KI Taylor","year":"2020","unstructured":"Taylor, K. I., Staunton, H., Lipsmeier, F., Nobbs, D. & Lindemann, M. Outcome measures based on digital health technology sensor data: data- and patient-centric approaches. NPJ Digit Med 3, 97 (2020).","journal-title":"NPJ Digit Med"},{"key":"607_CR40","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JPD-202346","volume":"11","author":"RJ Port","year":"2021","unstructured":"Port, R. J. et al. People with Parkinson\u2019s disease: What symptoms do they most want to improve and how does this change with disease duration? J. Parkinsons. Dis. 11, 715\u2013724 (2021).","journal-title":"J. Parkinsons. Dis."},{"key":"607_CR41","unstructured":"Jones, E., Oliphant, T. & Peterson, P. SciPy: Open Source Scientific Tools for Python (2001). http:\/\/www.scipy.org\/."},{"key":"607_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: A 2D Graphics Environment. Comput. Sci. Eng. 9, 90\u201395 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"607_CR43","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"M Waskom","year":"2021","unstructured":"Waskom, M. seaborn: statistical data visualization. J. Open Source Softw. 6, 3021 (2021).","journal-title":"J. Open Source Softw."},{"key":"607_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/mds.10011","volume":"17","author":"A Siderowf","year":"2002","unstructured":"Siderowf, A. et al. Test-retest reliability of the unified Parkinson\u2019s disease rating scale in patients with early Parkinson\u2019s disease: Results from a multicenter clinical trial. Mov. Disord. 17, 758\u2013763 (2002).","journal-title":"Mov. Disord."}],"updated-by":[{"DOI":"10.1038\/s41746-022-00744-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000}}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00607-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:49:44Z","timestamp":1700599784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00607-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1038\/s41746-022-00607-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.22.21268260","asserted-by":"object"}]},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"9 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41746-022-00744-0","URL":"https:\/\/doi.org\/10.1038\/s41746-022-00744-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors with Verily affiliation are current Verily employees and are Verily shareholders. The study is financially supported by Verily Life Sciences LLC, Radboud University Medical Center, Radboud University, the city of Nijmegen, and the Province of Gelderland. Radboud UMC received funding for the original cohort from Health Holland (PPP allowance; public-private partnership), Radboud University Radboudumc, and Radboudumc (in kind). The other study sponsors had no role in study design and collection, analysis and interpretation of data, or in writing the manuscript. Prof. Bloem serves as the co-Editor in Chief for the Journal of Parkinson\u2019s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for UCB, Kyowa Kirin, Zambon, and the Critical Path Institute (paid to the. Institute), has received fees for speaking at conferences from AbbVie, Biogen, UCB, Zambon, Roche, GE Healthcare, Oruen and Bial (paid to the Institute), and has received research support from the Netherlands Organization for Health Research and Development, the Michael J Fox Foundation, UCB, the Stichting Parkinson Fonds, Hersenstichting Nederland, de Stichting Woelse Waard, Stichting Alkemade-Keuls, de Maag Lever Darm Stichting, Parkinson NL, Davis Phinney Foundation, the Parkinson\u2019s Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, Nothing Impossible and the Parkinson Vereniging, outside the submitted work. Prof. Bloem does not hold any stocks or stock options with any companies that are connected to Parkinson\u2019s disease or to any of the topics in this paper. Prof. Bloem has received grants\/research support from Netherlands Organization for Scientific Research, the Michael J Fox Foundation, Nothing Impossible, Parkinson Vereniging, Parkinson\u2019s Foundation, Hersenstichting Nederland, Davis Phinney Foundation, Parkinson NL, Stichting Woelse Waard, Stichting Alkemade-Keuls, Maag Lever Darm Stichting, Verily Life Sciences, Horizon 2020, Topsector Life Sciences and Health, UCB, Zambon. Prof. Bloem has been a consultant for the Critical Path Institute, Kyowa Kirin, UCB, Zambon, and has received speaking fees from AbbVie, Bial, Biogen, GE Healthcare, Oruen, Roche, UCB, Zambon. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study is being conducted in conformance with the Good Clinical Practice ICH E6 guideline and in compliance with the Ethical Principles for Medical Research Involving Human Subjects, as defined in the Declaration of Helsinki (version amended in October 2013), the Dutch Personal Data Protection Act, and the European General Data Protection Regulation. The Commissie Mensgebonden Onderzoek Region Arnhem-Nijmegen approved the study protocol and communication materials<sup>27<\/sup>. Signed informed consent is obtained before engaging a participant in any study procedure, including use of the PD-VME.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"65"}}